China

Intelligence de marché des dispositifs médicaux pour China. Changements réglementaires, concurrents et tendances d'achats.

Table pays dernière MAJ : 9 août 2026 (peut être en retard). Le total 7 j est recalculé en direct (ancienne valeur table : 341).

Signaux / 7 j

799

Score d'activité (table)

NMPA

Class I-III Registration / CCC Certification

Dernier ingest: 16 sept. 2026 UTC

Signaux des 7 derniers jours

Tendance du marchéIngesté 16 sept. 2026· Source 16 sept. 2026

Pharmosa Biopharm's Inhaled Drug L606 Wins China Approval to Launch Global Phase 3 Trial for Pulmonary Hypertension - finance.biggo.com

Tendance du marchéIngesté 16 sept. 2026· Source 16 sept. 2026

Biogen (BIIB) Wins China Approval For At Home Weekly Alzheimer’s Treatment - simplywall.st

Tendance du marchéIngesté 15 sept. 2026

China NMPA Accelerates Market Access For Imported Medicines - insights.citeline.com

Tendance du marchéIngesté 15 sept. 2026· Source 15 sept. 2026

China approves third medical device standard for brain-computer interfaces - medicalbuyer.co.in

Tendance du marchéIngesté 11 sept. 2026· Source 11 sept. 2026

IceCure Secures China NMPA Approval for ProSense Cryoablation System - finance.yahoo.com

Tendance du marchéIngesté 10 sept. 2026· Source 10 sept. 2026

IceCure Medical (ICCM) secures China nod for tumor-freezing cancer tool - Stock Titan

Tendance du marchéIngesté 10 sept. 2026· Source 10 sept. 2026

China approves a tumor-freezing system from IceCure - Stock Titan

Tendance du marchéIngesté 10 sept. 2026· Source 10 sept. 2026

IceCure Medical Receives Regulatory Approval to Market ProSense® in China - PR Newswire